Adrenal Molecular Imaging.

2区医学 Q2 Medicine

Frontiers of Hormone Research Pub Date : 2016-03-15 DOI:10.1159/000442317

A. Sundin

{"title":"Adrenal Molecular Imaging.","authors":"A. Sundin","doi":"10.1159/000442317","DOIUrl":null,"url":null,"abstract":"The major workload in the field of adrenal imaging comprises patients with adrenal tumors incidentally depicted by imaging performed for other reasons than adrenal disease. These so-called 'incidentalomas' are generally managed by CT and MRI, and molecular imaging techniques are required only for a few patients. PET/CT with 18F-fluorodeoxyglucose (18F-FDG) is useful for establishing whether an adrenal metastasis is the only lesion, and therefore is available for surgical resection, or if the disease is disseminated. 18F-FDG PET/CT may be applied to differ benign from malignant incidentalomas and can be helpful in the imaging of pheochromocytoma and adrenocortical cancer (ACC). 11C-metomidate PET/CT can differentiate adrenocortical from nonadrenocortical tumors and a suspected ACC may be characterized and staged before surgery. 11C-metomidate PET/CT is currently also used to help diagnose Conn's adenomas in primary aldosteronism, but further development is needed. Scintigraphy with 123I/131I-metaiodobenzylguanidine (MIBG) remains the mainstay for molecular imaging of pheochromocytoma and is mandatory in patients for whom 131I-MIBG therapy is considered. A PET tracer for the imaging of pheochromocytoma is the norepinephrine analogue (11)C-hydroxyephedrine that can be used to characterize equivocal lesions and for the follow-up and diagnosis of recurrent malignant disease. Other specialized PET tracers for the imaging of pheochromocytoma are 18F-fluorodihydroxyphenylalanine (18F-DOPA) and 18F-fluorodopamine.","PeriodicalId":50428,"journal":{"name":"Frontiers of Hormone Research","volume":"45 1","pages":"70-9"},"PeriodicalIF":0.0000,"publicationDate":"2016-03-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1159/000442317","citationCount":"5","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Frontiers of Hormone Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1159/000442317","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 5

Abstract

The major workload in the field of adrenal imaging comprises patients with adrenal tumors incidentally depicted by imaging performed for other reasons than adrenal disease. These so-called 'incidentalomas' are generally managed by CT and MRI, and molecular imaging techniques are required only for a few patients. PET/CT with 18F-fluorodeoxyglucose (18F-FDG) is useful for establishing whether an adrenal metastasis is the only lesion, and therefore is available for surgical resection, or if the disease is disseminated. 18F-FDG PET/CT may be applied to differ benign from malignant incidentalomas and can be helpful in the imaging of pheochromocytoma and adrenocortical cancer (ACC). 11C-metomidate PET/CT can differentiate adrenocortical from nonadrenocortical tumors and a suspected ACC may be characterized and staged before surgery. 11C-metomidate PET/CT is currently also used to help diagnose Conn's adenomas in primary aldosteronism, but further development is needed. Scintigraphy with 123I/131I-metaiodobenzylguanidine (MIBG) remains the mainstay for molecular imaging of pheochromocytoma and is mandatory in patients for whom 131I-MIBG therapy is considered. A PET tracer for the imaging of pheochromocytoma is the norepinephrine analogue (11)C-hydroxyephedrine that can be used to characterize equivocal lesions and for the follow-up and diagnosis of recurrent malignant disease. Other specialized PET tracers for the imaging of pheochromocytoma are 18F-fluorodihydroxyphenylalanine (18F-DOPA) and 18F-fluorodopamine.

查看原文本刊更多论文

肾上腺分子成像。

肾上腺成像领域的主要工作量包括因肾上腺疾病以外的其他原因进行成像偶然描述的肾上腺肿瘤患者。这些所谓的“偶发瘤”通常通过CT和MRI进行治疗，只有少数患者需要分子成像技术。PET/CT与18f -氟脱氧葡萄糖(18F-FDG)有助于确定肾上腺转移是否是唯一的病变，因此可用于手术切除，或者如果疾病弥散。18F-FDG PET/CT可用于区分良性和恶性偶发瘤，并有助于嗜铬细胞瘤和肾上腺皮质癌(ACC)的成像。11C-metomidate PET/CT可区分肾上腺皮质与非肾上腺皮质肿瘤，疑似ACC可在术前进行特征和分期。11c -甲咪酯PET/CT目前也用于帮助诊断原发性醛固酮增多症的Conn腺瘤，但需要进一步发展。123I/131I-metaiodobenzylguanidine (MIBG)闪烁成像仍然是嗜铬细胞瘤分子成像的主要方法，对于考虑使用131I-MIBG治疗的患者是强制性的。一种用于嗜铬细胞瘤成像的PET示踪剂是去甲肾上腺素类似物(11)c -羟麻黄碱，可用于表征模棱两可的病变，并用于复发性恶性疾病的随访和诊断。其他用于嗜铬细胞瘤成像的专用PET示踪剂有18f -氟二羟基苯丙氨酸(18F-DOPA)和18f -氟多巴胺。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Frontiers of Hormone Research 医学-内分泌学与代谢

自引率

0.00%

发文量

期刊介绍： A series of integrated overviews on cutting-edge topics New sophisticated technologies and methodological approaches in diagnostics and therapeutics have led to significant improvements in identifying and characterizing an increasing number of medical conditions, which is particularly true for all aspects of endocrine and metabolic dysfunctions. Novel insights in endocrine physiology and pathophysiology allow for new perspectives in clinical management and thus lead to the development of molecular, personalized treatments. In view of this, the active interplay between basic scientists and clinicians has become fundamental, both to provide patients with the most appropriate care and to advance future research.